動物生物技術市場－全球產業規模、佔有率、趨勢、機會、預測：按產品類型、應用、動物類型、最終用途、地區和競爭格局分類，2021-2031年

全球動物生物技術市場預計將從 2025 年的 259.3 億美元成長到 2031 年的 452.9 億美元，複合年成長率為 9.74%。

在這個領域，分子生物學和基因工程的原理被應用於改造陸生和水生生物的基因組，以生產農業、工業和製藥領域的產品。推動該市場發展的主要動力是全球對優質動物蛋白日益成長的需求，這需要透過生物技術手段來提高動物的抗病能力和生產力。此外，人們對永續糧食安全的日益關注也促進了該產業的發展，加速了資源消耗更少、環境影響更小的動物品種的研發。聯合國糧食及農業組織（糧農組織）的報告也印證了這項需求：到2024年，全球肉類產量將成長1.7%，達到3.79億噸，這凸顯了開發先進生物技術解決方案以滿足不斷成長的供應需求的迫切性。

全球動物生物技術市場成長面臨的一大障礙是圍繞基因改造動物的複雜且往往分散的法規環境。不同國際司法管轄區在倫理標準上的差異以及缺乏統一的核准流程，造成了巨大的貿易壁壘，並延緩了創新產品的商業化。這種監管上的不確定性會增加研發所需的資金和時間，抑制投資，並有效阻礙產業內新技術的應用。

市場促進因素

伴侶動物醫療保健和健康產業的成長是市場擴張的主要驅動力，而寵物日益「人性化」的趨勢則進一步推動了這一成長。隨著飼主越來越重視寵物的壽命和生活品質，對精準醫療的需求日益成長，對基因篩檢和單株抗體療法等先進生物技術干預的需求也隨之增加。這種需求促使生物技術公司將人類醫療技術應用於獸醫領域，為產業擴張開闢了盈利的途徑。例如，美國寵物用品協會 (APPA) 在 2024 年 3 月發布的《產業趨勢》報告中指出，2023 年美國寵物產業的總支出將達到 1,474 億美元。這顯示消費者對動物福利的投資意願非常高，直接支持了專業生物製藥的研發和商業化。

此外，政府對獸醫生物技術研發的扶持和資助，透過降低早期創新和基礎設施建設的風險，正在增強市場成長勢頭。由於基因編輯和合成生物學等複雜技術在商業化之前往往面臨巨大的資金障礙，公共部門的津貼對其發展至關重要。例如，英國研究與創新署於2024年2月宣布投資1億英鎊，用於資助六個新的“工程生物學任務中心”，旨在解決包括食品系統在內的全球性挑戰。此類策略投資使私人企業能夠擴大營運規模，並更有效率地將科學突破推向全球市場。碩騰公司(Zoetis Inc.)的案例就充分體現了這種潛力，該公司在2024年2月發布的財報中公佈，其2023會計年度全年銷售額達85億美元。

市場挑戰

圍繞著基因改造動物的複雜且往往不一致的監管環境，對全球動物生物技術市場的成長構成了重大障礙。不同國際司法管轄區的核准流程和倫理指南存在差異，造成了巨大的貿易壁壘，迫使企業疲於應對錯綜複雜的創業投資要求，從而延緩了商業化進程。這種不協調性增加了研發者的財務風險。他們必須投入大量資源，卻無法保證進入全球市場，這反過來又阻礙了創投的進入，扼殺了創新。

這些監管負擔和由此導致的漫長研發週期加劇了挑戰，因為企業無法迅速收回投資。據動物健康研究所稱，到2024年，研發一種新的動物保健藥物平均需要8.5年時間，投資額約為3050萬美元。如此漫長的研發週期和高昂的資本支出阻礙了中小型生物技術公司進入該領域，並減緩了先進動物保健解決方案的整體普及，而這些解決方案對於滿足全球生產力需求至關重要。

市場趨勢

CRISPR-Cas9 和精準基因組編輯技術的廣泛應用正從實驗階段走向商業性化，從根本上改變了畜牧業疾病控制策略。基因編輯動物的監管進展便是這一趨勢的例證，這些動物旨在抵抗毀滅性病毒病原體，從而減少經濟損失並最大限度地降低畜牧業對藥物的依賴。這些基因改造性狀在食品供應鏈中的監管核准開始，證明了該技術的安全性和效用，標誌著市場發展的一個重要里程碑。根據 Genus plc 公司 2025 年 4 月發布的公告“抗豬繁殖與呼吸綜合症（PRRS）豬——獲 FDA核准”，美國食品藥物管理局（FDA）核准該公司生產的抗 PRRS 豬。這是應對該疾病的關鍵進展，因為該疾病會使受感染豬群的抗生素需求增加 200% 以上。

同時，在應對跨國動物疫病的迫切需求推動下，獸用疫苗領域正經歷著向基於DNA和mRNA的疫苗平台的重大轉變。各公司正積極投資建造專門的生產基礎設施，以處理這些複雜的生技藥品，從而擺脫傳統的、通常較為緩慢的疫苗生產方法。這種對先進聚合物生產能力​​的重視對於拓展新型治療和預防方案以滿足全球需求至關重要。根據默克動物保健公司2025年5月發布的題為「默克動物保健公司與堪薩斯州宣布8.95億美元投資」的新聞稿，該公司投資8.95億美元擴建其位於堪薩斯州德索託的工廠，特別是提升其聚合物疫苗和生物製藥的灌裝和凍乾能力。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：全球動物生物技術市場展望

• 市場規模及預測
  • 按金額
• 市佔率及預測
  • 產品類型（診斷測試、疫苗、藥品、生殖/遺傳相關產品、飼料添加物）
  • 應用領域（動物疾病診斷、動物疾病治療、動物預防醫學、藥物研發等）
  • 動物種類（伴侶動物、家畜）
  • 依最終用途（檢查室、就地檢驗/院內檢測、獸醫院/診所、其他）
  • 按地區
  • 按公司（2025 年）
• 市場地圖

第6章：北美動物生物技術市場展望

• 市場規模及預測
• 市佔率及預測
• 北美洲：國別分析
  • 美國
  • 加拿大
  • 墨西哥

第7章：歐洲動物生物技術市場展望

• 市場規模及預測
• 市佔率及預測
• 歐洲：國別分析
  • 德國
  • 法國
  • 英國
  • 義大利
  • 西班牙

第8章：亞太地區動物生物技術市場展望

• 市場規模及預測
• 市佔率及預測
• 亞太地區：國別分析
  • 中國
  • 印度
  • 日本
  • 韓國
  • 澳洲

第9章：中東和非洲動物生物技術市場展望

• 市場規模及預測
• 市佔率及預測
• 中東與非洲：國別分析
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 南非

第10章：南美洲動物生物技術市場展望

• 市場規模及預測
• 市佔率及預測
• 南美洲：國別分析
  • 巴西
  • 哥倫比亞
  • 阿根廷

第11章 市場動態

• 促進因素
• 任務

第12章 市場趨勢與發展

• 併購
• 產品發布
• 近期趨勢

第13章：全球動物生物技術市場：SWOT分析

第14章：波特五力分析

• 產業競爭
• 新進入者的潛力
• 供應商的議價能力
• 顧客權力
• 替代品的威脅

第15章 競爭格局

• Zoetis Inc
• Boehringer Ingelheim GmbH
• Biogenesis Bago SA
• Merck & Co., Inc.
• Virbac SA
• Elanco LLC
• IDEXX Laboratories Inc
• Heska Corp
• Indian Immunologicals Ltd
• Hester Biosciences Limited

第16章 策略建議

第17章：關於研究公司及免責聲明

The Global Animal Biotechnology Market is projected to expand from USD 25.93 Billion in 2025 to USD 45.29 Billion by 2031, registering a compound annual growth rate of 9.74%. This sector applies molecular biology and genetic engineering principles to alter the genomes of terrestrial and aquatic species for the creation of agricultural, industrial, and pharmaceutical products. A key force propelling this market is the rising global demand for high-quality animal protein, which necessitates biotechnological interventions to improve disease resistance and livestock productivity. Additionally, the industry is driven by an increasing focus on sustainable food security, encouraging the development of animals that require fewer resources and have a reduced environmental impact. Highlighting this need, the Food and Agriculture Organization reported that global meat production grew by 1.7% to 379 million tonnes in 2024, emphasizing the urgency for advanced biotechnological solutions to meet this escalating supply requirement.

A major obstacle potentially hindering the growth of the global animal biotechnology market is the complicated and often fragmented regulatory environment for genetically engineered animals. Differing ethical standards and inconsistent approval processes across various international jurisdictions create significant trade barriers and slow down the commercialization of innovative products. This regulatory uncertainty increases the capital and time needed for development, which can discourage investment and effectively stall the wider adoption of new technologies within the industry.

Market Driver

The growth of the companion animal healthcare and wellness sector serves as a primary catalyst for market progression, fueled by the increasing humanization of pets. As owners place greater importance on the longevity and quality of life of their animals, there is a distinct shift toward precision medicine, requiring advanced biotechnological interventions such as genetic screening and monoclonal antibody therapies. This demand prompts biotechnology firms to adapt human-grade medical technologies for veterinary use, opening up profitable avenues for industry expansion. For instance, the American Pet Products Association revealed in its March 2024 'State of the Industry' presentation that total U.S. pet industry expenditures hit $147.4 billion in 2023, indicating a robust consumer willingness to invest in animal well-being that directly supports the research and commercialization of specialized biopharmaceuticals.

Furthermore, government initiatives and funding for veterinary biotechnology research and development strengthen the market's trajectory by mitigating risks associated with early-stage innovation and infrastructure development. Public sector grants are crucial for advancing complex technologies like gene editing and synthetic biology, which often face high financial hurdles before becoming commercially viable. Illustrating this support, UK Research and Innovation announced in February 2024 a £100 million investment to fund six new Engineering Biology Mission Hubs aimed at addressing global challenges, including those in food systems. These strategic investments allow private entities to scale operations and bring scientific breakthroughs to the global market more efficiently, a potential evidenced by Zoetis Inc., which reported revenue of $8.5 billion for the full year 2023 in its February 2024 financial results.

Market Challenge

The intricate and often disjointed regulatory landscape governing genetically engineered animals constitutes a formidable barrier to the growth of the global animal biotechnology market. Disparate approval processes and varying ethical guidelines across international jurisdictions create significant trade hurdles, forcing companies to navigate a patchwork of compliance requirements that delays commercialization. This lack of harmonization increases the financial risk for developers, who must invest substantial resources without the guarantee of global market access, thereby deterring venture capital and stifling innovation.

The extended timelines associated with these regulatory burdens further exacerbate the challenge, as companies cannot quickly recoup their investments. According to the Animal Health Institute, in 2024, the development of a new livestock pharmaceutical required an average of 8.5 years and an investment of approximately $30.5 million. Such prolonged duration and high capital expenditure prevent smaller biotech firms from entering the sector and slow the overall adoption of advanced animal health solutions essential for meeting global productivity demands.

Market Trends

The widespread adoption of CRISPR-Cas9 and precision genome editing is transitioning from experimental phases to commercial reality, fundamentally altering livestock disease management strategies. This trend is exemplified by the regulatory progression of gene-edited animals designed to resist devastating viral pathogens, thereby reducing economic losses and minimizing the industry's reliance on pharmaceuticals. A pivotal market milestone occurred when regulatory bodies began clearing these engineered traits for the food supply chain, validating the technology's safety and utility. According to Genus plc, April 2025, in the 'PRRS Resistant Pig - FDA Approval' announcement, the U.S. Food and Drug Administration approved the company's PRRS-resistant pig, a development crucial for addressing a disease that increases the need for antibiotics by more than 200% in affected herds.

Concurrently, the sector is witnessing a decisive shift toward DNA and mRNA-based veterinary vaccine platforms, driven by the urgent need for rapid response capabilities against transboundary animal diseases. Companies are aggressively capitalizing specialized manufacturing infrastructure to support these complex biologics, moving away from slower, traditional vaccine production methods. This focus on advanced large-molecule production capacity is critical for scaling novel therapeutic and preventative solutions to meet global demand. According to Merck Animal Health, May 2025, in the 'Merck Animal Health and State of Kansas Announce $895 Million Investment' press release, the company allocated $895 million to expand its facility in De Soto, Kansas, specifically to enhance filling and freeze-drying capacity for large molecule vaccines and biologic products.

Key Market Players

• Zoetis Inc
• Boehringer Ingelheim GmbH
• Biogenesis Bago SA
• Merck & Co., Inc.
• Virbac SA
• Elanco LLC
• IDEXX Laboratories Inc
• Heska Corp
• Indian Immunologicals Ltd
• Hester Biosciences Limited

Report Scope

In this report, the Global Animal Biotechnology Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Animal Biotechnology Market, By Product Type

• Diagnostics Tests
• Vaccines
• Drugs
• Reproductive and Genetic
• Feed Additives

Animal Biotechnology Market, By Application

• Diagnosis of Animal Diseases
• Treatment of Animal Diseases
• Preventive Care of Animals
• Drug Development
• Others

Animal Biotechnology Market, By Animal Type

• Companion
• Livestock

Animal Biotechnology Market, By End-use

• Laboratories
• Point-of-care testing/In-house Testing
• Veterinary Hospitals & Clinics
• Others

Animal Biotechnology Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Animal Biotechnology Market.

Available Customizations:

Global Animal Biotechnology Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Animal Biotechnology Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Product Type (Diagnostics Tests, Vaccines, Drugs, Reproductive and Genetic, Feed Additives)
  • 5.2.2. By Application (Diagnosis of Animal Diseases, Treatment of Animal Diseases, Preventive Care of Animals, Drug Development, Others)
  • 5.2.3. By Animal Type (Companion, Livestock)
  • 5.2.4. By End-use (Laboratories, Point-of-care testing/In-house Testing, Veterinary Hospitals & Clinics, Others)
  • 5.2.5. By Region
  • 5.2.6. By Company (2025)
• 5.3. Market Map

6. North America Animal Biotechnology Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Product Type
  • 6.2.2. By Application
  • 6.2.3. By Animal Type
  • 6.2.4. By End-use
  • 6.2.5. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Animal Biotechnology Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Product Type
      • 6.3.1.2.2. By Application
      • 6.3.1.2.3. By Animal Type
      • 6.3.1.2.4. By End-use
  • 6.3.2. Canada Animal Biotechnology Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Product Type
      • 6.3.2.2.2. By Application
      • 6.3.2.2.3. By Animal Type
      • 6.3.2.2.4. By End-use
  • 6.3.3. Mexico Animal Biotechnology Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Product Type
      • 6.3.3.2.2. By Application
      • 6.3.3.2.3. By Animal Type
      • 6.3.3.2.4. By End-use

7. Europe Animal Biotechnology Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Product Type
  • 7.2.2. By Application
  • 7.2.3. By Animal Type
  • 7.2.4. By End-use
  • 7.2.5. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Animal Biotechnology Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Product Type
      • 7.3.1.2.2. By Application
      • 7.3.1.2.3. By Animal Type
      • 7.3.1.2.4. By End-use
  • 7.3.2. France Animal Biotechnology Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Product Type
      • 7.3.2.2.2. By Application
      • 7.3.2.2.3. By Animal Type
      • 7.3.2.2.4. By End-use
  • 7.3.3. United Kingdom Animal Biotechnology Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Product Type
      • 7.3.3.2.2. By Application
      • 7.3.3.2.3. By Animal Type
      • 7.3.3.2.4. By End-use
  • 7.3.4. Italy Animal Biotechnology Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Product Type
      • 7.3.4.2.2. By Application
      • 7.3.4.2.3. By Animal Type
      • 7.3.4.2.4. By End-use
  • 7.3.5. Spain Animal Biotechnology Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Product Type
      • 7.3.5.2.2. By Application
      • 7.3.5.2.3. By Animal Type
      • 7.3.5.2.4. By End-use

8. Asia Pacific Animal Biotechnology Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Product Type
  • 8.2.2. By Application
  • 8.2.3. By Animal Type
  • 8.2.4. By End-use
  • 8.2.5. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Animal Biotechnology Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Product Type
      • 8.3.1.2.2. By Application
      • 8.3.1.2.3. By Animal Type
      • 8.3.1.2.4. By End-use
  • 8.3.2. India Animal Biotechnology Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Product Type
      • 8.3.2.2.2. By Application
      • 8.3.2.2.3. By Animal Type
      • 8.3.2.2.4. By End-use
  • 8.3.3. Japan Animal Biotechnology Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Product Type
      • 8.3.3.2.2. By Application
      • 8.3.3.2.3. By Animal Type
      • 8.3.3.2.4. By End-use
  • 8.3.4. South Korea Animal Biotechnology Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Product Type
      • 8.3.4.2.2. By Application
      • 8.3.4.2.3. By Animal Type
      • 8.3.4.2.4. By End-use
  • 8.3.5. Australia Animal Biotechnology Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Product Type
      • 8.3.5.2.2. By Application
      • 8.3.5.2.3. By Animal Type
      • 8.3.5.2.4. By End-use

9. Middle East & Africa Animal Biotechnology Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Product Type
  • 9.2.2. By Application
  • 9.2.3. By Animal Type
  • 9.2.4. By End-use
  • 9.2.5. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Animal Biotechnology Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Product Type
      • 9.3.1.2.2. By Application
      • 9.3.1.2.3. By Animal Type
      • 9.3.1.2.4. By End-use
  • 9.3.2. UAE Animal Biotechnology Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Product Type
      • 9.3.2.2.2. By Application
      • 9.3.2.2.3. By Animal Type
      • 9.3.2.2.4. By End-use
  • 9.3.3. South Africa Animal Biotechnology Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Product Type
      • 9.3.3.2.2. By Application
      • 9.3.3.2.3. By Animal Type
      • 9.3.3.2.4. By End-use

10. South America Animal Biotechnology Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Product Type
  • 10.2.2. By Application
  • 10.2.3. By Animal Type
  • 10.2.4. By End-use
  • 10.2.5. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Animal Biotechnology Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Product Type
      • 10.3.1.2.2. By Application
      • 10.3.1.2.3. By Animal Type
      • 10.3.1.2.4. By End-use
  • 10.3.2. Colombia Animal Biotechnology Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Product Type
      • 10.3.2.2.2. By Application
      • 10.3.2.2.3. By Animal Type
      • 10.3.2.2.4. By End-use
  • 10.3.3. Argentina Animal Biotechnology Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Product Type
      • 10.3.3.2.2. By Application
      • 10.3.3.2.3. By Animal Type
      • 10.3.3.2.4. By End-use

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Animal Biotechnology Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Zoetis Inc
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Boehringer Ingelheim GmbH
• 15.3. Biogenesis Bago SA
• 15.4. Merck & Co., Inc.
• 15.5. Virbac SA
• 15.6. Elanco LLC
• 15.7. IDEXX Laboratories Inc
• 15.8. Heska Corp
• 15.9. Indian Immunologicals Ltd
• 15.10. Hester Biosciences Limited

16. Strategic Recommendations

17. About Us & Disclaimer